摘要
探讨阿格列汀联合甘精胰岛素治疗低C肽水平老年成人隐匿性自身免疫性糖尿病(LADA)的临床疗效。选取2020年5月至2023年5月秦皇岛市第二医院收治的142例低C肽水平老年LADA患者作为研究对象,按照随机数字表法分为观察组(n=71)及对照组(n=71)。对照组予以甘精胰岛素,观察组予以阿格列汀联合甘精胰岛素,两组均治疗6个月。比较2组疗效、治疗前后糖代谢指标、胰岛功能、脂代谢指标、安全性。观察组总有效率为91.55%(65/71),高于对照组78.87%(56/71)(P<0.05);治疗6个月后,两组糖化血红蛋白(HbA1c)、空腹血糖(FBG)、餐后2 h血糖(2hPG)低于治疗前,观察组低于对照组(P<0.05);治疗6个月后,两组胰岛β细胞功能指数(HOMA-β)、空腹C肽高于治疗前,观察组高于对照组(P<0.05);治疗6个月后,两组胰岛素抵抗指数(HOMA-IR)低于治疗前,观察组低于对照组(P<0.05);治疗6个月后,两组低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)低于治疗前,观察组低于对照组(P<0.05);两组不良反应发生率为9.87%(7/71)及7.05%(5/71),差异无统计学意义(P>0.05)。阿格列汀联合甘精胰岛素能调节低C肽水平老年LADA患者糖代谢,促进脂代谢恢复,改善胰岛功能,疗效确切。
In order to explore the clinical curative effect of alogliptin combined with insulin glargine in the elderly with low C-peptide latent autoimmune diabetes in adults(LADA),142 elderly patients with with low C-peptide LADA in Qinhuangdao Second Hospital were enrolled as the research objects between May 2020 and May 2023.According to random number table method,they were divided into observation group(n=71)and control group(n=71).The control group was treated with insulin glargine,while observation group was treated with alogliptin+insulin glargine for 6 months.The curative effect,glucose metabolism indexes,islet function,lipid metabolism indexes and adverse reactions in the two groups were compared before and after treatment.The total response rate in observation group was 91.55%(65/71),higher than that in control group[78.87%(56/71),P<0.05].After 6 months of treatment,glycated hemoglobin(HbA1c),fasting blood glucose(FBG)and 2 h postprandial blood glucose(2hPG)were decreased in both groups,which were lower in observation group than those in control group(P<0.05).After 6 months of treatment,levels of isletβcell function index(HOMA-β)and fasting C-peptide were increased in both groups,which were higher in observation group than those in control group(P<0.05).After 6 months of treatment,insulin resistance index(HOMA-IR)was decreased in both groups,which was lower in observation group than that in control group(P<0.05).After 6 months of treatment,low-density lipoprotein cholesterol(LDL-C),triglyceride(TG)and total cholesterol(TC)were decreased in both groups,which were lower in observation group than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups[9.87%(7/71)vs 7.05%(5/71),P>0.05].Alogliptin combined with insulin glargine can regulate glucose metabolism,promote recovery of lipid metabolism and improve islet function in elderly patients with low C-peptide LADA,which has significant curative effect.
作者
常杨
赵艳荣
CHANG Yang;ZHAO Yanrong(Department of Endocrinology,Qinhuangdao Second Hospital,Qinhuangdao 066600,China)
出处
《药物生物技术》
CAS
2024年第3期295-298,共4页
Pharmaceutical Biotechnology
基金
秦皇岛市科学技术研究与发展计划项目(No.201805A148)。
关键词
成人隐匿性自身免疫性糖尿病
老年
阿格列汀
甘精胰岛素
C肽
糖代谢
胰岛功能
脂代谢
latent autoimmune diabetes in adult
elderly
alogliptin
insulin glargine
C-peptide
glucose metabolism
islet function
lipid metabolism
